ACP
APLS

Altitude Crest Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Altitude Crest Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-287,277
Closed -$16.9M – 4
2024
Q1 		$16.9M Buy
287,277
+135,077
+89% +$8.61M 7.23% 5
2023
Q4 		$9.11M Buy
+152,200
New +$7.72M 6.1% 6

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Altitude Crest Partners's APLS Position: Q2 2024 in Review

Altitude Crest Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 287,277 shares — an estimated $16.9M sold.

Altitude Crest Partners first reported a position in APLS in Q4 2023 and held it in 2 quarters. The position peaked at $16.9M in Q1 2024. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Altitude Crest Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 287,277 Apellis Pharmaceuticals shares in Q2 2024, an estimated $16.9M.
  • Altitude Crest Partners first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Altitude Crest Partners's Apellis Pharmaceuticals position peaked at $16.9M in Q1 2024.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.